Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1592.4000 -12.45 (-0.78%)

NSE Mar 28, 2025 15:31 PM

28.30% Fall from 52W High

Volume: 60,089

Gland Pharma Ltd.

21 Jul 2021

1592.40

-0.78%

Complex products/newer markets to fortify growth pace

Buy: Gland Pharma Ltd.

Motilal Oswal

GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification. We raise our FY22E/FY23E EPS estimate by 8% each to factor in: a) increased reach as well as penetration in the RoW/India markets, b) better outlook for the US market, c) higher offtake of Remdesivir/Enoxaparin, and d)...

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.